David S. Hong, MD

Articles

Dr Hong on Preliminary Activity With RMC-6291 in Advanced KRAS G12C–Mutant Solid Tumors

October 18th 2023

David S. Hong, MD, discusses preliminary efficacy data from a phase 1 trial f the KRAS G12C inhibitor RMC-6291 in advanced KRAS G12C–mutant solid tumors.

Dr. Hong on the Significance of Larotrectinib in NTRK-Positive NSCLC

August 7th 2022

David S. Hong, MD, discusses the significance of larotrectinib in the treatment of non–small cell lung cancer and other solid tumors harboring NTRK gene fusions.

Dr. Hong on Comparing the Use of Sotorasib and Adagrasib in CRC

April 14th 2022

David S. Hong, MD, discusses data examining the use of sotorasib (Lumakras) and adagrasib in colorectal cancer.

Dr. Hong on Objectives of the CodeBreaK 101 Trial in CRC

March 2nd 2022

David S. Hong, MD, discusses the primary objective of the ongoing phase 1/2 CodeBreaK 101 trial in mutated advanced colorectal cancer and other solid tumors harboring KRAS G12C mutations.

Dr. Hong on the Efficiency of the CodeBreaK 101 Trial in KRAS G12C-Mutated CRC and Other Solid Tumors

January 22nd 2022

David S. Hong, MD, discusses the efficiency of the ongoing phase 1/2 CodeBreaK 101 trial in KRAS G12C-mutated advanced colorectal cancer and other solid tumors.

Dr. Hong on the Potential Clinical Implications of the SURPASS Trial in Gastric/GEJ Cancer

January 18th 2021

David S. Hong, MD, discusses the potential clinical implications of the phase 1 SURPASS trial in gastric/gastroesophageal junction cancer.

Dr. Hong on Moving Tisotumab Vedotin to Frontline Therapy for Cervical Cancer

October 18th 2019

David S. Hong, MD, discusses the potential of moving tisotumab vedotin (HuMax-TF-ADC) to the frontline setting in cervical cancer.

Dr. Hong on the Mechanism of Action of Tisotumab vedotin in Cervical Cancer

June 25th 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

Dr. Hong on the Design of the InnovaTV 201 Trial in Cervical Cancer

May 23rd 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the InnovaTV 201 trial in cervical cancer.

Dr. Hong on the Safety Profile of Tisotumab Vedotin in Cervical Cancer

May 16th 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

Dr. Hong on Results of the Phase II innovaTV 201 Study

March 19th 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics and associate vice president of clinical research at The University of Texas MD Anderson Cancer Center, discusses the promising results of the phase II innovaTV 201 study, in which tisotumab vedotin was used to treat patients with previously treated recurrent or metastatic cervical cancer.

Dr. Hong Discusses IPI-549 in Advanced Solid Tumors

November 17th 2017

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses IPI-549 during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.